Literature DB >> 23976771

The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD).

Diana R Mager1, Ingrid Rivera Iñiguez2, Susan Gilmour3, Jason Yap3.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a common liver disease in obese children. Diets high in added fructose (high fructose corn syrup; HFCS) and glycemic index (GI)/glycemic load (GL) are associated with increased risk of NAFLD. Lifestyle modification is the main treatment, but no guidelines regarding specific dietary interventions for childhood NAFLD exist. We hypothesized that reductions in dietary fructose (total, free, and HFCS)/GI/GL over 6 months would result in improvements in body composition and markers of liver dysfunction and cardiometabolic risk in childhood NAFLD.
METHODS: Children and adolescents with NAFLD (n = 12) and healthy controls (n = 14) 7-18 years were studied at baseline and 3 and 6 months post-dietary intervention. Plasma markers of liver dysfunction (ALT, AST, γGT), cardiometabolic risk (TG, total cholesterol, LDL-HDL cholesterol, Apo-B100, Apo-B48, Apo-CIII, insulin, homeostasis model of assessment of insulin resistance [HOMA-IR]), inflammation (TNF-α, IL-6, IL-10), anthropometric, and blood pressure (BP) were studied using validated methodologies.
RESULTS: Significant reductions in systolic BP (SBP), percentage body fat (BF), and plasma concentrations of ALT (P = .04), Apo-B100 (P < .001), and HOMA-IR were observed in children with NAFLD at 3 and 6 months (P < .05). Dietary reductions in total/free fructose/HFCS and GL were related to reductions in SBP (P = .01), ALT (P = .004), HOMA-IR (P = .03), and percentage BF in children with NAFLD. Reductions in dietary GI were associated with reduced plasma Apo-B100 (P = .02) in both groups. With the exception of Apo-B100, no changes in laboratory variables were observed in the control group.
CONCLUSION: Modest reductions in fructose (total/free, HFCS) and GI/GL intake result in improvements of plasma markers of liver dysfunction and cardiometabolic risk in childhood NAFLD.
© 2013 American Society for Parenteral and Enteral Nutrition.

Entities:  

Keywords:  children; glycemic index; glycemic load; high fructose corn syrup; metabolic dysregulation; nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2013        PMID: 23976771     DOI: 10.1177/0148607113501201

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  29 in total

1.  Intensive lifestyle treatment for non-alcoholic fatty liver disease in children with severe obesity: inpatient versus ambulatory treatment.

Authors:  B G P Koot; O H van der Baan-Slootweg; S Vinke; A E Bohte; C L J Tamminga-Smeulders; P L M Jansen; J Stoker; M A Benninga
Journal:  Int J Obes (Lond)       Date:  2015-08-28       Impact factor: 5.095

2.  Parental perceptions regarding lifestyle interventions for obese children and adolescents with nonalcoholic fatty liver disease.

Authors:  Ingrid Rivera Iñiguez; Jason Yap; Diana R Mager
Journal:  Paediatr Child Health       Date:  2014-05       Impact factor: 2.253

Review 3.  Clinical advances in pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer
Journal:  Hepatology       Date:  2016-03-04       Impact factor: 17.425

Review 4.  Lifestyle Intervention as the Primary Treatment for Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Taisa Kohut; Jennifer Panganiban
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

5.  Risk factors for progression of and treatment options for NAFLD in children.

Authors:  Phillipp Hartmann; Bernd Schnabl
Journal:  Clin Liver Dis (Hoboken)       Date:  2018-01-31

Review 6.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

Review 7.  Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.

Authors:  Samir Softic; David E Cohen; C Ronald Kahn
Journal:  Dig Dis Sci       Date:  2016-02-08       Impact factor: 3.199

Review 8.  Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field.

Authors:  Miriam B Vos
Journal:  Curr Opin Lipidol       Date:  2014-02       Impact factor: 4.776

9.  Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling.

Authors:  Samir Softic; Manoj K Gupta; Guo-Xiao Wang; Shiho Fujisaka; Brian T O'Neill; Tata Nageswara Rao; Jennifer Willoughby; Carole Harbison; Kevin Fitzgerald; Olga Ilkayeva; Christopher B Newgard; David E Cohen; C Ronald Kahn
Journal:  J Clin Invest       Date:  2017-10-03       Impact factor: 14.808

10.  Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity.

Authors:  Jean-Marc Schwarz; Susan M Noworolski; Ayca Erkin-Cakmak; Natalie J Korn; Michael J Wen; Viva W Tai; Grace M Jones; Sergiu P Palii; Moises Velasco-Alin; Karen Pan; Bruce W Patterson; Alejandro Gugliucci; Robert H Lustig; Kathleen Mulligan
Journal:  Gastroenterology       Date:  2017-06-01       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.